ctrl K

Watchlist Price Alert

Adamas Pharmaceuticals In... (ADMS)

NASDAQ: ADMS · Real-Time Price · USD

8.22

0.00 (0.00%)

At close: Apr 24, 2025, 3:47 PM

Adamas Pharmaceuticals Income Statement

Financials in USD. Fiscal year is undefined.

Fiscal Year	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	74.46M	54.64M	34.05M	571K	572K
Cost of Revenue	2.04M	2.47M	633K	17K	n/a
Gross Profit	72.42M	52.17M	33.41M	554K	572K
Operating Income	-44.16M	-92.23M	-115.02M	-87.93M	-60.98M
Interest Income	748K	2.09M	3.12M	1.35M	811K
Pretax Income	-57.4M	-105.19M	-131M	-91.22M	-60.17M
Net Income	-57.4M	-105.19M	-131M	-89.49M	-60.06M
Selling & General & Admin	106.84M	114.37M	109.14M	61.31M	30.33M
Research & Development	9.75M	30.03M	39.3M	27.17M	31.23M
Other Expenses	n/a	n/a	n/a	n/a	n/a
Operating Expenses	116.59M	144.4M	148.44M	88.48M	61.56M
Interest Expense	13.24M	15.04M	19.09M	4.64M	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	118.63M	146.87M	149.07M	88.5M	61.56M
Income Tax Expense	n/a	2.09M	3.12M	-1.73M	-115K
Shares Outstanding (Basic)	35.17M	27.68M	26.89M	22.56M	21.71M
Shares Outstanding (Diluted)	35.17M	27.68M	26.89M	22.56M	21.71M
EPS (Basic)	-1.63	-3.8	-4.87	-3.97	-2.77
EPS (Diluted)	-1.63	-3.8	-4.87	-3.97	-2.77
EBITDA	-43.31M	-88.93M	-110.45M	-85.38M	-59.37M
EBIT	n/a	-90.14M	-111.91M	-86.58M	n/a
Depreciation & Amortization	851K	1.21M	1.46M	1.19M	808K